Soren Lykke Petersen
Overview
Explore the profile of Soren Lykke Petersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen S, Ostrowski S, Andersen N, Friis L, Kornblit B, Petersen S, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39978734
Circulating nucleosomes are representative of cell death, which is a feature of acute graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We explored whether plasma nucleosome levels were...
2.
Schovsbo J, Kjeldsen L, Norskov K, Sengelov H, Kornblit B, Schjodt I, et al.
Transplant Cell Ther
. 2024 Nov;
31(1):28.e1-28.e10.
PMID: 39522721
Allogenic hematopoietic cell transplantation (allo-HCT) with myeloablative conditioning traditionally requires 30 days of hospitalization after stem cell infusion. However, advancements in supportive and prophylactic care have allowed for a trend...
3.
Agner B, Riley C, Petersen S, Spanggaard I, Hutchings M, Rohrberg K, et al.
Ugeskr Laeger
. 2024 Mar;
186(9).
PMID: 38445322
T-cell-based immunotherapy has recently evolved as a treatment option for a number of haematological malignancies and is also being developed in solid tumours. A common side effect of chimeric antigen...
4.
Jespersen F, Petersen S, Andersen P, Sellebjerg F, Magyari M, Soelberg Sorensen P, et al.
Mult Scler Relat Disord
. 2023 Jun;
76:104829.
PMID: 37364374
Background: Autologous hematopoietic stem cell treatment (AHSCT) is considered an effective treatment option for patients with aggressive relapsing-remitting multiple sclerosis (RRMS). Still there are few randomized and controlled studies of...
5.
Wegener A, Andersen N, Friis L, Petersen S, Schjodt I, Kornblit B, et al.
Transplant Cell Ther
. 2023 Jun;
29(9):575.e1-575.e6.
PMID: 37301257
Adding sirolimus to graft-versus-host disease (GVHD) prophylaxis with cyclosporin and mycophenolate mofetil (MMF) reduced the risk of grade II-IV acute GVHD after nonmyeloablative (NMA) allogenic hematopoietic stem cell transplantation (HSCT)...
6.
Gjaerde L, Ostrowski S, Schierbeck F, Andersen N, Friis L, Kornblit B, et al.
Transplant Cell Ther
. 2022 Nov;
29(2):97.e1-97.e6.
PMID: 36375798
Soluble ST2 is established as a prognostic biomarker of nonrelapse mortality (NRM) when measured early after allogeneic hematopoietic cell transplantation (HCT). However, less is known about the prognostic value of...
7.
Gjaerde L, Ostrowski S, Jorgensen N, Schierbeck F, Andersen N, Friis L, et al.
Transpl Immunol
. 2022 Jun;
74:101650.
PMID: 35718288
Background: Low pre-transplantation plasma vitamin E levels have been associated with increased risk of acute graft-versus-host disease (GvHD) after myeloablative allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to investigate the...
8.
Sengelov H, Petersen S
Ugeskr Laeger
. 2021 Oct;
183(42).
PMID: 34709159
Malignant hematologic diseases resistant to chemotherapy can be cured by immune cellular therapy. Bone marrow transplantation (BMT) elicits a "pan-immunologic" attack, whereas therapy with chimeric antigen receptor (CAR)-T is a...
9.
Gjaerde L, Rank C, Klarskov Andersen M, Jakobsen L, Sengelov H, Olesen G, et al.
Leuk Lymphoma
. 2021 Oct;
63(2):416-425.
PMID: 34672245
We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of...
10.
Gjaerde L, Ostrowski S, Andersen N, Friis L, Kornblit B, Petersen S, et al.
Transpl Immunol
. 2021 Jul;
68:101437.
PMID: 34273495
Background: The association between vitamin D and acute graft-versus-host disease (GvHD) remains controversial, especially for patients receiving myeloablative conditioning. Methods: We measured pre-transplantation plasma vitamin D (25-hydroxyvitamin D + D)...